Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Farnesyltransferase, CAAX box, alpha (FNTA)
- Target
- FNTA
- Molecular classification
- Enzyme, Prenyltransferase, Protein modifying enzyme
01
Overview
Farnesyltransferase, CAAX box, alpha (FNTA) encodes the alpha subunit shared by protein farnesyltransferase and protein geranylgeranyltransferase type-1, which is essential for the prenylation of proteins containing a C-terminal CAAX motif. Preylation by these enzymes ensures the proper localization and function of various signaling proteins, including Ras and Rac1, and is implicated in cancer, metabolic, and neurodegenerative diseases. While FNTA is a validated therapeutic target, its related pseudogenes (including FNTAP1) are not known to encode active proteins nor are they clinically targeted[1][3].
- Other names
- Protein Farnesyltransferase/Geranylgeranyltransferase Type-1 Subunit AlphaPGGT1APTAR2FPTARas Proteins Prenyltransferase Subunit AlphaProtein Prenyltransferase Alpha Subunit Repeat Containing 2Farnesyltransferase, CAAX box, alpha
02
Mechanism of action
Inhibition of protein prenylation (blocks attachment of farnesyl/geranylgeranyl to target proteins, e.g., Ras)
03
Biological functions
Protein prenylation (catalyzes transfer of farnesyl/geranylgeranyl group to CAAX-motif proteins)Membrane localization of target proteinsSignal transduction (downstream Ras, Rac1)Modulation of neuromuscular junction development (via RAC1 prenylation)Metabolic regulation (influences apolipoprotein A-I secretion)
04
Disease associations
Cancer (breast, bladder)Neurodegenerative diseases (Huntington’s disease)Cardiovascular disease (via metabolic effects)Diabetes (diabetic retinopathy)Endocrine tumors, dystonia
05
Safety considerations
Potential toxicity from interfering with essential signaling pathways (Ras, Rac1)Off-target effects (prenylation is necessary for many cellular functions; global inhibition may have broad impact)
06
Interacting drugs
Farnesyltransferase inhibitors such as tipifarnib, lonafarnib, and other experimental anticancer agents
07
Biomarkers
FNTA expression (as a marker for cancer progression/aggressiveness and chemoresistance)Prenylated Ras/Rac1 as indicators of pathway activation
Beyond the preview
Go deeper on Farnesyltransferase, CAAX box, alpha (FNTA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Farnesyltransferase, CAAX box, alpha (FNTA).